Cardiomyopathy Medication Market Size, Key Vendors, Demand, Development Strategy Demographic, Geographic Segment by 2030
Cardiomyopathy Medication Market is expected to grow from USD 800.87 Million in 2018 to USD 620 Million by 2030 at a CAGR of 4.85%.

Cardiomyopathy Medication Market Overview

The Global Cardiomyopathy Medication Market Size is anticipated to reach USD 620 Million by 2025 at a CAGR of ~4.60% during the forecast period of 2019 to 2025.

Cardiomyopathy is a disease that causes the thickening and enlargement of the heart muscles and abnormal blood flow. Patients suffering from cardiomyopathy showcase symptoms such as dizziness, coughing, fatigue, and swelling of the legs, ankles, and feet.

Certain factors that propel the growth of the global Cardiomyopathy Medication Market Size are the high patient pool of heart disease, focus on manufacturing medication for cardiomyopathy treatment, and rising healthcare expenditure. 

Currently, the global Cardiomyopathy Medication Market Size is dominated by several players. The major players in this market are involved in strategic acquisitions and product launches to expand their product portfolios. For instance, in May 2019, Pfizer Inc. received US FDA approval for Vyndamax (tafamidis) and Vyndaqel (tafamidis meglumine) for the treatment of cardiomyopathy.

However, the side effects associated with the medication and presence of alternative treatment methods are expected to hinder the growth of the global Cardiomyopathy Medication Market Size during the forecast period.

Request Free Sample Copy at:


The global Cardiomyopathy Medication Market Size has also been segmented based on type, treatment, and end user.

Based on type, the market has been segmented into dilated cardiomyopathy, hypertrophic cardiomyopathy, restrictive cardiomyopathy, arrhythmogenic right ventricular dysplasia, and unclassified cardiomyopathy. The dilated cardiomyopathy segment is projected to hold the largest share of the market due to the presence of a large patient population. The hypertrophic cardiomyopathy segment is expected to be the fastest-growing wing to the increasing prevalence of hypertrophic cardiomyopathy across the globe. 

By treatment, the global Cardiomyopathy Medication Market Size has been categorized as anticoagulants, antiarrhythmics, antihypertensives, cardiac glycosides, and diuretics. The anti-hypertensives segment has been further divided into ACE inhibitors, angiotensin II receptor blockers, beta-blockers, and calcium channel blockers. The anti-hypertensives segment is expected to be the largest due to the increasing demand for and high prescription rate of these medicines for heart disease patients.  Antiarrhythmics is anticipated to be the fastest-growing segment due to the increasing preference for antiarrhythmics drug in emergency situations to prevent heart attacks and strokes.

The end user segments of the market are homecare, hospitals and clinics, and others. The hospitals and clinics segment is expected to dominate the market during the review period. The growth of the segment can be attributed to the high number of patients visiting such institutions for diagnosis and treatment.  Homecare is projected to be the fastest-growing segment.

Regional Analysis

The global Cardiomyopathy Medication Market Size has been segmented, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The Cardiomyopathy Medication Market Size in the Americas has further been segmented into North America and Latin America, with the North American market divided into the US and Canada. The European Cardiomyopathy Medication Market Size has been divided into Western Europe and Eastern Europe. The market in Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe. The Cardiomyopathy Medication Market Size in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The Cardiomyopathy Medication Market Size in the Middle East & Africa has been divided into the Middle East and Africa. The market in the Americas is expected to dominate the global Cardiomyopathy Medication Market Size due to the increasing per capita healthcare expenditure and presence of a large number of healthcare companies in the region. The market in Asia-Pacific is projected to register the highest growth rate during the forecast period owing to the increasing awareness of cardiac diseases and increasing government initiatives for healthcare reforms.

Cardiomyopathy Medication Market Players

Some of the key players in the global Cardiomyopathy Medication Market Size are Pfizer Inc. (US), PhaseBio Pharmaceuticals, Inc. (US), Array Biopharma, Inc. (US), AstraZeneca (UK), Sanofi-Aventis US LLC (US), F. Hoffmann-La Roche Ltd (UK), Merck & Co., Inc. (US), Capricor Therapeutics (US), MyoKardia (US), Janssen Products, LP (US), Ionis Pharmaceuticals, Inc. (US), Medtronic (Ireland), Becton And Dickson & Co. (US), Biomerieux (UK), and Teva Pharmaceutical Industries Ltd (Israel).

among others are some key companies in the global Cardiomyopathy Medication that are listed by MRFR for market research.

Browse Detailed TOC with COVID-19 Impact Analysis at:

About Market Research Future:

At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), & Consulting Services. MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients.

Contact us:

Market Research Future (part of Wantstats Research and Media Private Limited),

99 Hudson Street, 5Th Floor,

New York, New York 10013

United States of America

+1 646 845 9312